Evidence map›Paper›PMID 41949116›Full record

Trial reportFuture oncology (London, England)2026

Lorlatinib in patients with

Alessandra Bearz, Serena Ricciardi, Nirmal Vivek Raut, Manuel Cobo Dols, Satheesh Chiradoni Thungappa, Paola Claudia Sacco, Holger Thurm, Dmitri Pavlov, Francesca Toffalorio, Enriqueta Felip

Registry-linked trialAbstract readClinical Trial, Phase IVMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04362072 (Single-Arm Study of Lorlatinib in Participants With Anaplastic Lymphoma Kinase), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04362072 phase4completednot on this map

Single-Arm Study of Lorlatinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) Whose Disease Progressed After One Prior Second-Generation ALK Tyrosine Kinase Inhibitor (TKI)

TypeinterventionalSponsorPfizerRan2020 to 2024Enrolled71ConditionsCarcinoma, Non-Small-Cell LungArmsLorlatinib
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alessandra BearzMedical Oncology Department, CRO Aviano, National Cancer Institute IRCCS, Aviano, Italy.ORCID 0000-0003-1020-2338
Serena RicciardiOncology Pneumology, San Camillo-Forlanini Hospital, Roma, Italy.ORCID 0000-0001-5401-4836
Nirmal Vivek RautMedical Oncology, Jupiter Hospital, Pune, India.
Manuel Cobo DolsMedical Oncology, Hospital Regional Universitario de Málaga, Málaga, Spain.ORCID 0000-0003-3402-1144
Satheesh Chiradoni ThungappaDepartment of Medical Oncology, HCG Oncology, Bengaluru, India.
Paola Claudia SaccoDepartment of Oncology, S.G. Moscati Hospital, Avellino, Italy.
Holger ThurmOncology Research & Development, Pfizer, San Diego, CA, USA.ORCID 0009-0008-7700-4970
Dmitri PavlovOncology Research & Development, Pfizer, San Diego, CA, USA.
Francesca ToffalorioOncology Research & Development, Pfizer, Milan, Italy.
Enriqueta FelipMedical Oncology Department, Vall d'Hebron Institute of Oncology, Barcelona, Spain.ORCID 0000-0002-7620-0098

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThis post-approval study was conducted to confirm efficacy of lorlatinib in anaplastic lymphoma kinase ( PATIENTS &

methodsIn this phase IV open-label study, patients with

resultsAmong 71 patients treated with lorlatinib, 85% had received prior alectinib and 15% received prior ceritinib. Median duration of lorlatinib treatment was 9.7 months. ORR was 42% (95% CI, 31%-55%); median duration of response was not reached. Median progression-free survival was 12.2 months (95% CI, 6.9-22.1). In patients with central nervous system metastases (

conclusionsThese phase IV efficacy and safety results remained consistent with the pivotal phase I/II study. Lorlatinib continued to show clinically meaningful benefit in patients with previously treated CLINICAL

trial registrationclinicaltrials.gov identifier is NCT04362072.

Indexed as

AminopyridinesAnaplastic Lymphoma KinaseCarcinoma, Non-Small-Cell LungLactams, MacrocyclicLung NeoplasmsProtein Kinase InhibitorsAdultAgedAged, 80 and overFemaleHumansLactamsMaleMiddle AgedNeoplasm MetastasisPiperidinesALK protein, humanAminopyridinesAnaplastic Lymphoma KinaseLactamsLactams, MacrocycliclorlatinibPiperidinesProtein Kinase InhibitorsPyrazolesalectinibALK-positiveLorlatinibnon-small cell lung cancerphase IV

Identifiers

PMID41949116
PMCPMC13089924

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.